russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2022-5194russjcardiol-5194Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯCLINIC AND PHARMACOTHERAPYГиперурикемия как фактор риска сердечно-сосудистых осложнений у пациентов с артериальной гипертониейHyperuricemia as a risk factor for cardiovascular events in hypertensive patientshttps://orcid.org/0000-0002-0912-6342ЛибовИ. А.LibovI. A.

Врач-кардиолог консультативного отделения, старший научный сотрудник подразделения "Наука"

Москва

Moscow

igor.libov@mail.ruhttps://orcid.org/0000-0002-5000-5454МоисееваЮ. Н.MoiseevaYu. N.

Врач-кардиолог консультативного отделения № 2 КДЦ

Москва

Moscow

КомароваА. Г.KomarovaA. G.

Заместитель главного врача

Москва

Moscow

Городская клиническая больница им. С. П. Боткина Департамента здравоохранения г. МосквыРоссияS.P. Botkin Moscow City Clinical HospitalRussian Federation20222008202227951945194Copyright © Либов И.А., Моисеева Ю.Н., Комарова А.Г., 20222022Либов И.А., Моисеева Ю.Н., Комарова А.Г.Libov I.A., Moiseeva Y.N., Komarova A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/5194

Артериальная гипертензия (АГ) остается одним из важнейших факторов риска развития сердечно-сосудистых осложнений. Коррекция дополнительных факторов риска, наряду со снижением значений артериального давления, в значительной степени влияет на прогноз развития сердечно-сосудистых событий. Гиперурикемия – один из новых факторов риска, имеющий высокую распространенность в популяции и влияющий на прогноз развития сердечно-сосудистых осложнений у больных с АГ. При лечении фиксированными комбинациями у пациентов с АГ и гиперурикемией особое значение при выборе препарата приобретает метаболическая нейтральность. При назначении диуретиков практикующий врач сталкивается с дополнительными трудностями. Эти препараты обладают высоким синергизмом при добавлении к другим основным классам гипотензивных средств, но, в ряде случаев, могут ухудшать метаболический профиль. Применение тиазидоподобного диуретика индапамида позволяет в большей части избежать отрицательного влияния на метаболический профиль, что делает его более предпочтительным при выборе диуретика у пациентов с гиперурикемией.

Hypertension (HTN) remains one of the most important risk factors for cardiovascular events. Modification of additional risk factors, along with a blood pressure decrease, significantly affects the risk of cardiovascular events. Hyperuricemia is one of the new factors that has a high prevalence in the population and affects the risk for cardiovascular events in hypertensive patients. In the treatment with fixed-dose combinations in patients with hypertension and hyperuricemia, metabolic neutrality is of particular importance. When prescribing diuretics, the practitioner faces additional difficulties. These drugs are highly synergistic when added to other major antihypertensives’ classes, but, in some cases, may worsen the metabolic profile. The use of the thiazide-like diuretic indapamide largely avoids a negative effect on the metabolic profile, making it the preferred choice for patients with hyperuricemia.

артериальная гипертонияфакторы рискагиперурикемиямочевая кислотадиуретикииндапамидhypertensionrisk factorshyperuricemiauric aciddiureticsindapamideReferencesRapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases, lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899-911. doi:10.1016/S0140-6736(14)60685-1.Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases, lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899-911. doi:10.1016/S0140-6736(14)60685-1.Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-anayses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285-95. doi:10.1097/HJH.0000000000000378.Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-anayses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285-95. doi:10.1097/HJH.0000000000000378.Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower0than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003;361:1149-58. doi:10.2165/00003495-200464002-00005.Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower0than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003;361:1149-58. doi:10.2165/00003495-200464002-00005.Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.Кобалава Ж.Д., Конради А.О., Недогода С.В. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.Loyola Correa T, Oliveira I. Association between serum urate and inflammatory markers in young adults: cross-sectional findings from a birth cohort. Annals of the Rheumatic Diseases. 2021;80:1004.2-1004.10. doi:10.1136/annrheumdis-2021-eular.3790.Loyola Correa T, Oliveira I. Association between serum urate and inflammatory markers in young adults: cross-sectional findings from a birth cohort. Annals of the Rheumatic Diseases. 2021;80:1004.2-1004.10. doi:10.1136/annrheumdis-2021-eular.3790.Katsiki N, Papanas N, Fonseca VA, et al. Uric acid and diabetes: Is there a link. Curr Pharm Des. 2013;19(27):4930-7. doi:10.2174/1381612811319270016.Katsiki N, Papanas N, Fonseca VA, et al. Uric acid and diabetes: Is there a link. Curr Pharm Des. 2013;19(27):4930-7. doi:10.2174/1381612811319270016.Maloberti A, Giannattasio C, Bombelli M, et al.; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press Cardiovasc Prev. 2020;27(2):121-8. doi:10.1007/s40292-020-00368-z.Maloberti A, Giannattasio C, Bombelli M, et al.; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press Cardiovasc Prev. 2020;27(2):121-8. doi:10.1007/s40292-020-00368-z.Georgiopoulos G, Tsioufis C, Kalos T et al. Serum Uric Acid is Independently Associated with Diastolic Dysfunction in Apparently Healthy Subjects with Essential Hypertension. Curr Vasc Pharmacol. 2019;17(1):99-106. doi:10.2174/1570161116666171226124959.Georgiopoulos G, Tsioufis C, Kalos T et al. Serum Uric Acid is Independently Associated with Diastolic Dysfunction in Apparently Healthy Subjects with Essential Hypertension. Curr Vasc Pharmacol. 2019;17(1):99-106. doi:10.2174/1570161116666171226124959.Tu CM, Tseng GS, Liu CW. Serum Uric Acid may be Associated with Left Ventricular Diastolic Dysfunction in Military Individuals. Mil Med. 2020:usaa413. doi:10.1093/milmed/usaa413. Epub ahead of print.Tu CM, Tseng GS, Liu CW. Serum Uric Acid may be Associated with Left Ventricular Diastolic Dysfunction in Military Individuals. Mil Med. 2020:usaa413. doi:10.1093/milmed/usaa413. Epub ahead of print.Podpalova O, Mrochek A. High level of serum uric acid is a predictor of development of carotid artery plaques in new cases of hypertension in urban randomized population regardless of metabolic syndrome. Journal of Hypertension. 2019;37:e281. doi:10.1097/01.hjh.0000573588.73767.d8.Podpalova O, Mrochek A. High level of serum uric acid is a predictor of development of carotid artery plaques in new cases of hypertension in urban randomized population regardless of metabolic syndrome. Journal of Hypertension. 2019;37:e281. doi:10.1097/01.hjh.0000573588.73767.d8.Шальнова С.А., Деев А.Д., Артамонова Г.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014;10(2):153-9. doi:10.20996/1819-6446-2014-10-2-153-159.Shalnova SA, Deev AD, Artamonov GV, et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF epidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):153-9. (In Russ.) doi:10.20996/1819-6446-2014-10-2-153-159.Wu AH, Gladden JD, Ahmed M, et al. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016;213:4-7. doi:10.1016/j.ijcard.2015.08.110.Wu AH, Gladden JD, Ahmed M, et al. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016;213:4-7. doi:10.1016/j.ijcard.2015.08.110.Hou L, Zhang M, Han W, et al. Influence of Salt Intake on Association of Blood Uric Acid with Hypertension and Related Cardiovascular Risk. PLoS One. 2016;11(4):e0150451. doi:10.1371/journal.pone.0150451.Hou L, Zhang M, Han W, et al. Influence of Salt Intake on Association of Blood Uric Acid with Hypertension and Related Cardiovascular Risk. PLoS One. 2016;11(4):e0150451. doi:10.1371/journal.pone.0150451.Leiba A, Vinker S, Dinour D, et al. Uric acid levels within the normal range predict increased risk of hypertension: a cohort study. J Am Soc Hypertens. 2015;9(8):600-9. doi:10.1016/j.jash.2015.05.010.Leiba A, Vinker S, Dinour D, et al. Uric acid levels within the normal range predict increased risk of hypertension: a cohort study. J Am Soc Hypertens. 2015;9(8):600-9. doi:10.1016/j.jash.2015.05.010.Ando K, Takahashi H, Watanabe T, et al. Impact of Serum Uric Acid Levels on Coronary Plaque Stability Evaluated Using Integrated Backscatter Intravascular Ultrasound in Patients with Coronary Artery Disease. J Atheroscler Thromb. 2016;23(8):932-9. doi:10.5551/jat.33951.Ando K, Takahashi H, Watanabe T, et al. Impact of Serum Uric Acid Levels on Coronary Plaque Stability Evaluated Using Integrated Backscatter Intravascular Ultrasound in Patients with Coronary Artery Disease. J Atheroscler Thromb. 2016;23(8):932-9. doi:10.5551/jat.33951.Dai XM, Wei L, Ma LL, et al. Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease. Clin Rheumatol. 2015;34(9):1605-11. doi:10.1007/s10067-015-2878-1.Dai XM, Wei L, Ma LL, et al. Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease. Clin Rheumatol. 2015;34(9):1605-11. doi:10.1007/s10067-015-2878-1.Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мильто А.С. Мочевая кислота — ключевой компонент "кардиоренометаболического континуума". Кардиоваскулярная терапия и профилактика. 2008;7(4):95-100. EDN ILJVLN.Kobalava ZD, Kotovskaya YuV, Tolkacheva VV, Milto AS. Uric acid — the key component of "cardio-reno-metabolic continuum". Cardiovascular Therapy and Prevention. 2008;7(4):95- 100. (In Russ.)Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-10. doi:10.1002//acr.20344.Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-10. doi:10.1002//acr.20344.Kuwabara M, Borghi C, Cicero AFG, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. Int J Cardiol. 2018;261:183-8. doi:10.1016/j.ijcard.2018.03.045.Kuwabara M, Borghi C, Cicero AFG, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. Int J Cardiol. 2018;261:183-8. doi:10.1016/j.ijcard.2018.03.045.Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases: Five-Year Japanese Cohort Study. Hypertension. 2017;69(6):1036-44. doi:10.1161/HYPERTENSIONAHA.116.08998.Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases: Five-Year Japanese Cohort Study. Hypertension. 2017;69(6):1036-44. doi:10.1161/HYPERTENSIONAHA.116.08998.Cuspidi C, Facchetti R, Bombelli M, et al. Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population. Am J Hypertens. 2017;30(3):279-85. doi:10.1093/ajh/hpw159.Cuspidi C, Facchetti R, Bombelli M, et al. Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population. Am J Hypertens. 2017;30(3):279-85. doi:10.1093/ajh/hpw159.Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998;158:741-51. doi:10.1001/archinte.158.7.741.Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998;158:741-51. doi:10.1001/archinte.158.7.741.Peterzan MA, Hardy R, Chaturvedi N, et al. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59:1104-9. doi:10.1161/HYPERTENSIONAHA.111.190637.Peterzan MA, Hardy R, Chaturvedi N, et al. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59:1104-9. doi:10.1161/HYPERTENSIONAHA.111.190637.Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf. 2001;24:1155- 65. doi:10.2165/00002018-200124150-00006.Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf. 2001;24:1155- 65. doi:10.2165/00002018-200124150-00006.Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustainedrelease indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens. 1998;16:1677-84. doi:10.1097/00004872-199816110-00015.Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustainedrelease indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens. 1998;16:1677-84. doi:10.1097/00004872-199816110-00015.Puig JG, Marre M, Kokot F, et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens. 2007;20(1):90-7. doi:10.1016/j.amjhyper.2006.05.018.Puig JG, Marre M, Kokot F, et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens. 2007;20(1):90-7. doi:10.1016/j.amjhyper.2006.05.018.Semenkin AA, Zhivilova LA, Golevtsova Z, et al. Comparative assessment of hypotensive, metabolic, and endothelial effects of indapamide-retard and hydrochlorothiazide in patients with essential hypertension. Kardiologiia. 2006;46:35-9. EDN XWMGNV.Semenkin AA, Zhivilova LA, Golevtsova Z, et al. Comparative assessment of hypotensive, metabolic, and endothelial effects of indapamide-retard and hydrochlorothiazide in patients with essential hypertension. Kardiologiia. 2006;46:35-9. EDN XWMGNV.Musini VM, Nazer M, Bassett K, et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5:CD003824. doi:10.1002/14651858.CD003824.pub2.Musini VM, Nazer M, Bassett K, et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5:CD003824. doi:10.1002/14651858.CD003824.pub2.Мазуров А. Л., Трухан Д.И. Сравнительная характеристика индапамида и гидрохлоротиазида. Современные наукоемкие технологии. 2010;2:100-1. EDN KZKVYJ.Mazurov AL, Trukhan DI. Comparative characteristics of indapamide and hydrochlorothyazide. Modern high technologies 2010;2:100-1. (In Russ.)Farsang С, Dézsi С, Brzozowska-Villatte R, et al. Beneficial Effects of a Perindopril/ Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. Adv Ther. 2021;38:1776-90.Farsang С, Dézsi С, Brzozowska-Villatte R, et al. Beneficial Effects of a Perindopril/ Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. Adv Ther. 2021;38:1776-90.Кобалава Ж.Д., Толкачева В.В., Багманова Н.Х. и др. Эффективность и переносимость Арифама у пациентов с артериальной гипертонией старше 55 лет: основные результаты наблюдательной программы АРБАЛЕТ. Российский кардиологический журнал. 2018;23(12):64-74. doi:10.15829/1560-4071-2018-12-64-74.Kobalava ZD, Tolkacheva VV, Bagmanova NK, et al. Efficacy and tolerance of Arifam in patients with arterial hypertension over 55 years old: main results of the observational program ARBALET. Russian Journal of Cardiology. 2018;(12):64-74. (In Russ.) doi:10.15829/1560-4071-2018-12-64-74.Tóth K, PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/ indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137-45. doi:10.1007/s40256-014-0067-2.Tóth K, PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/ indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137-45. doi:10.1007/s40256-014-0067-2.Кобалава Ж.Д., Троицкая Е.А., Толкачева В.В. Комбинированная терапия артериальной гипертонии с использованием трехкомпонентной фиксированной комбинации амлодипина, индапамида и периндоприла аргинина в клинической практике: организация и основные результаты программы ДОКАЗАТЕЛЬСТВО. Кардиология. 2018;58(9):21-30. doi:10.18087/cardio.2018.9.10170.Kobalava ZhD, Troitskaya EA, Tolkacheva VV. Combined Therapy of Arterial Hypertension With Triple Fixed-Dose Combination of Amlodipine/Indapamide/Perindopril Arginine in Real Clinical Practice: the Organization and the Main Results of the DOKAZATEL’STVO (Proof) Study. Kardiologiia. 2018;58(9):21-30. (In Russ.) doi:10.18087/cardio.2018.9.10170.

The authors declare that there are no conflicts of interest present.